|
|
|
Volumn 5, Issue 1, 2003, Pages 76-80
|
|
Technology evaluation: ISIS-104838, OraSense
a
a
NONE
(United Kingdom)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANALGESIC AGENT;
ANTIINFLAMMATORY AGENT;
ANTIRHEUMATIC AGENT;
ANTISENSE OLIGONUCLEOTIDE;
ETANERCEPT;
GOLD COMPLEX;
INFLIXIMAB;
ISIS 104838;
MESSENGER RNA;
METHOTREXATE;
MONOCLONAL ANTIBODY;
PLACEBO;
TUMOR NECROSIS FACTOR ALPHA;
TUMOR NECROSIS FACTOR ALPHA ANTIBODY;
TUMOR NECROSIS FACTOR ALPHA RECEPTOR;
UNCLASSIFIED DRUG;
ARTHRALGIA;
CLINICAL TRIAL;
CROHN DISEASE;
DOSE RESPONSE;
DRUG ABSORPTION;
DRUG ACTIVITY;
DRUG BIOAVAILABILITY;
DRUG DESIGN;
DRUG EFFICACY;
DRUG ELIMINATION;
DRUG HYPERSENSITIVITY;
DRUG MARKETING;
DRUG METABOLISM;
DRUG RECEPTOR BINDING;
DRUG SAFETY;
DRUG SYNTHESIS;
ERYTHEMA;
HEADACHE;
HUMAN;
INFLAMMATORY DISEASE;
LICENSING;
MALE;
NONHUMAN;
POMPHOLYX;
PSORIASIS;
RASH;
REVIEW;
RHEUMATOID ARTHRITIS;
SKIN ABRASION;
THROMBOCYTOPENIA;
ANTI-INFLAMMATORY AGENTS;
ARTHRITIS, RHEUMATOID;
CLINICAL TRIALS;
CROHN DISEASE;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
OLIGONUCLEOTIDES, ANTISENSE;
PSORIASIS;
RNA, MESSENGER;
TECHNOLOGY ASSESSMENT, BIOMEDICAL;
TUMOR NECROSIS FACTOR-ALPHA;
POMPHOLYX;
|
|
EID: 0037298737
PISSN: 14648431
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (17)
|
|
References (0)
|
